Cozaar®
Losartan is an angiotensin II receptor blocker (ARB) for hypertension, diabetic nephropathy, and stroke risk reduction. First ARB to reach market.
| Dosage Form | Oral Tablet (Film-Coated) |
| Strength | 25 mg, 50 mg, 100 mg |
| Storage | Store at 25°C. Protect from light. |
| Category | Cardiovascular |
| Availability | Available for Transfer |
Hypertension; diabetic nephropathy (in T2DM with proteinuria); stroke risk reduction in hypertension with LVH.
Selectively blocks angiotensin II type 1 (AT1) receptor, preventing angiotensin II-mediated vasoconstriction, aldosterone release, and cardiovascular remodeling.
Each Burrard Pharmaceuticals technology transfer package for Losartan includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier templates — available through Burrard Intelligence subscription.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Our team can deliver the complete know-how package within 2–21 business days. Book a consultation to discuss your specific requirements.